SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Varenhorst Eberhard 1937 )
 

Sökning: WFRF:(Varenhorst Eberhard 1937 ) > Prospective evaluat...

Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate

Spetz, Anna-Clara, 1973- (författare)
Linköpings universitet,Obstetrik och gynekologi,Hälsouniversitetet
Hammar, Mats, 1950- (författare)
Linköpings universitet,Obstetrik och gynekologi,Hälsouniversitetet
Lindberg, Bengt (författare)
Department of Surgery, Kungälv Hospital, Kungälv, Sweden
visa fler...
Spångberg, Anders, 1945- (författare)
Linköpings universitet,Urologi,Hälsouniversitetet
Varenhorst, Eberhard, 1937- (författare)
Linköpings universitet,Urologi,Hälsouniversitetet
visa färre...
 (creator_code:org_t)
2001
2001
Engelska.
Ingår i: Journal of Urology. - 0022-5347 .- 1527-3792. ; 166:2, s. 517-520
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • PurposeWe evaluated the incidence and frequency of, and distress due to hot flashes after castration therapy with polyestradiol phosphate and complete androgen ablation.Materials and MethodsA total of 915 men with metastatic prostate carcinoma enrolled in the Scandinavian Prostatic Cancer Group-5 trial study were randomized to intramuscular injections of 240 mg. Polyestradiol phosphate every 2 weeks for 8 weeks followed by monthly subcutaneous injections or complete androgen ablation, that is bilateral orchiectomy or 3.75 mg. of the gonadotropin-releasing hormone analog triptorelin monthly combined with 250 mg. of the antiandrogen flutamide 3 times daily. The incidence and frequency of, and distress due to hot flashes were recorded at regular intervals using a questionnaire.ResultsOf the 915 men 901 were evaluated at a median followup of 18.5 months. The incidence of hot flashes was 30.1% and 74.3% in the polyestradiol phosphate and complete androgen ablation groups, respectively (p <0.001). In the polyestradiol phosphate group the frequency of and distress due to hot flashes were significantly lower than in the androgen ablation group. There was complete relief from hot flashes in 50% of the men on polyestradiol phosphate during followup compared with none on androgen ablation. The incidence of hot flashes did not differ in men with and without tumor progression.ConclusionsEndocrine treatment with polyestradiol phosphate induced fewer and less distressing hot flashes than complete androgen ablation. Flashes also disappeared to a greater extent during polyestradiol phosphate than during androgen ablation. The data in this study enable us to provide thorough individual information to patients on the risk and grade of expected distress and duration of hot flashes during polyestradiol phosphate or complete androgen ablation treatment.

Nyckelord

MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy